To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
Public ClinicalTrials.gov record NCT02121210. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Primary Objective: To evaluate the immunogenicity of sarilumab administered as monotherapy. Secondary Objectives: * To evaluate the other safety aspects of sarilumab administered as monotherapy. * To assess the exposure of sarilumab administered as monotherapy.
Study identification
- NCT ID
- NCT02121210
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 132 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2014
- Primary completion
- Apr 30, 2015
- Completion
- Apr 30, 2015
- Last update posted
- Jun 19, 2017
2014 – 2015
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 840072 | Gilbert | Arizona | 85234 | — |
| Investigational Site Number 840049 | Upland | California | 91786 | — |
| Investigational Site Number 840220 | South Miami | Florida | 33143 | — |
| Investigational Site Number 840230 | Elizabethtown | Kentucky | 42701 | — |
| Investigational Site Number 840233 | Minot | North Dakota | 58701 | — |
| Investigational Site Number 840127 | Oklahoma City | Oklahoma | 73103 | — |
| Investigational Site Number 840011 | Tulsa | Oklahoma | 74104 | — |
| Investigational Site Number 840009 | Duncansville | Pennsylvania | 16635 | — |
| Investigational Site Number 840025 | Jackson | Tennessee | 38305 | — |
| Investigational Site Number 840032 | Amarillo | Texas | 79124 | — |
| Investigational Site Number 840074 | Mesquite | Texas | 75150 | — |
| Investigational Site Number 840124 | Clarksburg | West Virginia | 26301 | — |
| Investigational Site Number 840231 | Franklin | Wisconsin | 53132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02121210, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 19, 2017 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02121210 live on ClinicalTrials.gov.